{
  "id": "5c6b7fb27c78d6947100002d",
  "type": "factoid",
  "question": "Burosumab is used for treatment of which disease?",
  "ideal_answer": "Burosumab is a fully human IgG1 monoclonal antibody directed at fibroblast growth factor 23 (FGF23), is indicated for the treatment of X-linked hypophosphatemia (XLH), a condition associated with excessive FGF23 production.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29896030",
    "http://www.ncbi.nlm.nih.gov/pubmed/29679282",
    "http://www.ncbi.nlm.nih.gov/pubmed/30459508",
    "http://www.ncbi.nlm.nih.gov/pubmed/30269120",
    "http://www.ncbi.nlm.nih.gov/pubmed/30207609",
    "http://www.ncbi.nlm.nih.gov/pubmed/29791829",
    "http://www.ncbi.nlm.nih.gov/pubmed/29381780",
    "http://www.ncbi.nlm.nih.gov/pubmed/29545670",
    "http://www.ncbi.nlm.nih.gov/pubmed/29947083"
  ],
  "snippets": [
    {
      "text": "In particular, a humanized monoclonal antibody for FGF23 (burosumab) is a promising treatment in patients with XLH and TIO. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29381780",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In February 2018, the EMA granted subcutaneous burosumab conditional marketing authorization for the treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. In April 2018, the US FDA approved burosumab for the treatment of XLH in adults and children one year of age and older. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29679282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29791829",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Burosumab-twza (Crysvita) for a rare inherited form of rickets; ibalizumab-uiyk (Trogarzo) for human immunodeficiency virus type 1 infection; and tildrakizumab-asmn (Ilumya) for adults with moderate-to-severe plaque psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29896030",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29947083",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These data support the conclusion that burosumab is a novel therapeutic addressing an important medical need in adults with XLH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29947083",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A novel therapy for XLH directly targeting fibroblast growth factor-23 via a humanized monoclonal antibody (burosumab-twza/CRYSVITA, henceforth referred to just as burosumab) has emerged as an effective, and recently approved, pharmacological treatment for both children and adults. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30207609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Burosumab in X-linked hypophosphatemia: a profile of its use in the USA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459508",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Burosumab (Crysvita\u00ae), a fully human IgG1 monoclonal antibody directed at fibroblast growth factor 23 (FGF23), is indicated for the treatment of X-linked hypophosphatemia (XLH), a condition associated with excessive FGF23 production. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In clinical trials, subcutaneous burosumab increased serum phosphorus levels in pediatric and adult patients with XLH, as well as significantly improving the severity of rickets in children, and improving pain, stiffness, physical functioning, and fracture/pseudofracture healing in adults. Burosumab is well tolerated by children and adults with XLH, with most treatment-emergent adverse events being of mild to moderate severity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, Burosumab is being tested as a potential treatment for patients with tumor-induced osteomalacia(TIO), which is the most prevalent form of acquired FGF23-related hypophosphatemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30269120",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In particular, a humanized monoclonal antibody for FGF23 (burosumab) is a promising treatment in patients with XLH and TIO. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29381780",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In April 2018, the US FDA approved burosumab for the treatment of XLH in adults and children one year of age and older. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29679282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Burosumab is well tolerated by children and adults with XLH, with most treatment-emergent adverse events being of mild to moderate severity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inhibition of FGF23 by burosumab results in increased renal phosphate reabsorption and increased serum levels of phosphorus and active vitamin D. In February 2018, the EMA granted subcutaneous burosumab conditional marketing authorization for the treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29679282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Burosumab (Crysvita\u00ae), a fully human IgG1 monoclonal antibody directed at fibroblast growth factor 23 (FGF23), is indicated for the treatment of X-linked hypophosphatemia (XLH), a condition associated with excessive FGF23 production.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Burosumab is well tolerated by children and adults with XLH, with most treatment-emergent adverse events being of mild to moderate severity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In clinical trials, subcutaneous burosumab increased serum phosphorus levels in pediatric and adult patients with XLH, as well as significantly improving the severity of rickets in children, and improving pain, stiffness, physical functioning, and fracture/pseudofracture healing in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inhibition of FGF23 by burosumab results in increased renal phosphate reabsorption and increased serum levels of phosphorus and active vitamin D. In February 2018, the EMA granted subcutaneous burosumab conditional marketing authorization for the treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29679282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In April 2018, the US FDA approved burosumab for the treatment of XLH in adults and children one year of age and older.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29679282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of burosumab leading to its first global approval in the EU for XLH in paediatric patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29679282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In particular, a humanized monoclonal antibody for FGF23 (burosumab) is a promising treatment in patients with XLH and TIO.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29381780",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, Burosumab is being tested as a potential treatment for patients with tumor-induced osteomalacia(TIO), which is the most prevalent form of acquired FGF23-related hypophosphatemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30269120",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A novel therapy for XLH directly targeting fibroblast growth factor-23 via a humanized monoclonal antibody (burosumab-twza/CRYSVITA, henceforth referred to just as burosumab) has emerged as an effective, and recently approved, pharmacological treatment for both children and adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30207609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29791829",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29545670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, Burosumab is being tested as a potential treatment for patients with tumor-induced osteomalacia(TIO), which is the most prevalent form of acquired FGF23-related hypophosphatemia.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30269120",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The safety and efficacy of a human anti-FGF23 antibody, KRN23 or burosumab, has been confirmed in adults and children with XLHR.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30269120",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These data support the conclusion that burosumab is a novel therapeutic addressing an important medical need in adults with XLH.\u00a9 2018 The Authors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29947083",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These data support the conclusion that burosumab is a novel therapeutic addressing an important medical need in adults with XLH.\u00a9 2018 The Authors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29947083",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29791829",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "X-linked hypophosphatemia"
}